^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoCompass™ Target

    Company:
    Burning Rock Biotech
    Type:
    CE Marked
    Related tests:
    over1year
    Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib (IASLC-WCLC 2023)
    The EGFRexon20ins concordance between tumor tissue-based and plasma ctDNA testing is high. Antitumor activity of sunvozertinib was robust regardless of tumor tissue-based or plasma ctDNA tests. Both tests can be applied for identifying patients who potentially benefit from sunvozertinib treatment.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • KIT mutation • EGFR exon 20 mutation
    |
    OncoCompass™ Target • OncoScreen™ Focus CDx Tissue Kit
    |
    sunvozertinib (DZD9008)
    3years
    Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock’s OncoCompass Target (Burning Rock Dx Press Release)
    "Burning Rock Biotech Limited...announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market. The CDx test is based on Burning Rock's self-developed next generation sequencing (NGS)-based liquid biopsy solution, OncoCompass Target™ panel....Tepotinib was the first oral MET inhibitor to receive a regulatory approval anywhere in the world for the treatment of advanced non-small cell lung cancer (NSCLC) harboring MET gene alterations..."
    Licensing / partnership
    |
    OncoCompass™ Target
    |
    Tepmetko (tepotinib)
    3years
    OncoCompass™ Target: Pivotal study launch in 2H21 (Burning Rock Biotech)
    Investor Presentation
    New trial
    |
    OncoCompass™ Target